G1 Therapeutics’ (GTHX) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a report published on Monday morning, RTT News reports. They currently have a $3.00 price objective on the stock, down from their previous price objective of $5.00.

A number of other brokerages have also recently issued reports on GTHX. Needham & Company LLC reissued a buy rating and issued a $12.00 target price on shares of G1 Therapeutics in a report on Thursday, June 13th. HC Wainwright reissued a buy rating and issued a $9.00 price target on shares of G1 Therapeutics in a report on Tuesday, May 28th.

G1 Therapeutics Stock Performance

G1 Therapeutics stock opened at $2.22 on Monday. G1 Therapeutics has a 52 week low of $1.08 and a 52 week high of $6.14. The company has a current ratio of 2.94, a quick ratio of 2.55 and a debt-to-equity ratio of 1.34. The stock has a market cap of $116.06 million, a P/E ratio of -3.58 and a beta of 1.71. The stock has a 50 day moving average of $3.75 and a 200-day moving average of $3.60.

G1 Therapeutics (NASDAQ:GTHX) last issued its earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. The company had revenue of $14.48 million during the quarter, compared to analyst estimates of $15.21 million. During the same quarter last year, the company posted ($0.53) EPS. On average, analysts expect that G1 Therapeutics will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On G1 Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Financial Advocates Investment Management acquired a new position in shares of G1 Therapeutics in the fourth quarter worth about $39,000. SG Americas Securities LLC purchased a new stake in shares of G1 Therapeutics in the 1st quarter valued at approximately $58,000. Creative Financial Designs Inc. ADV boosted its stake in G1 Therapeutics by 98.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after purchasing an additional 17,475 shares during the period. Capstone Investment Advisors LLC purchased a new position in G1 Therapeutics during the 4th quarter worth approximately $76,000. Finally, Jump Financial LLC purchased a new position in G1 Therapeutics during the 4th quarter worth approximately $105,000. Institutional investors and hedge funds own 24.21% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.